৳ 350/unit
Pack: ৳ 350
৳ 350/unit
Pack: ৳ 350
At a glance
Recombinant fusion protein used in combination with FOLFIRI chemotherapy for metastatic colorectal cancer (mCRC).
Indications
Indicated in combination with FOLFIRI for patients with metastatic colorectal cancer (mCRC) resistant to or progressed following an oxaliplatin-containing regimen.
Pharmacology
Aflibercept functions as a decoy receptor binding to VEGF-A and PlGF, preventing them from activating VEGFR-1 and VEGFR-2 receptors, thus suppressing neovascularization and vascular permeability.
Dosage
4 mg/kg as an intravenous infusion over 1 hour every 2 weeks. Do not administer as an IV push or bolus.
Side effects
Common: Leukopenia, diarrhea, neutropenia, proteinuria, AST/ALT elevation, stomatitis, fatigue, thrombocytopenia, hypertension, weight decrease, epistaxis, abdominal pain, and dysphonia.
Use in pregnancy
Pregnancy Category C. Embryotoxic and teratogenic in animal studies. Effective contraception required during treatment and for 3 months after last dose.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Precautions & warnings
Monitor for fistula formation, hypertensive crisis, arterial thromboembolic events, proteinuria, severe diarrhea, and Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Delay if neutrophils < 1.5 x 10^9/L.
Overdose effects
No reported cases of overdose. Doses > 7 mg/kg every 2 weeks lack safety data. Provide supportive care.
Storage conditions
Store in refrigerator at 2° to 8°C. Keep vial in original carton to protect from light. Do not freeze.